Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33)
National Institutes of Health (NIH)
About this opportunity
November 22, 2024 - Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed). See NOFO RFA-HL-26-017. National Institute of Allergy and Infectious Diseases (NIAID) This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective for due dates on or after June 18, 2026, in the Notice of Funding Opportunity Announcement (NOFO) RFA-HL-26-017, "Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)". The f...